| Field | Specification |
|---|---|
| Target | |
| Alternative names | Atlastin-1; ATL-1; Brain-specific GTP-binding protein; GTP-binding protein 3; GBP-3; hGBP3; Guanine nucleotide-binding protein 3; Spastic paraplegia 3 protein A; ATL1; GBP3; SPG3; SPG3A |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human SPG3A/ATL1, which shares 93.8% and 100% amino acid (aa) sequence identity with mouse and rat ATL1, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets atlastin-1 (gene ATL1) in human samples and is validated for Western blot, IHC and flow cytometry. The predicted molecular weight is 63.5 kDa, and the supplier reports an observed band at about 64 kDa.
Atlastin-1 (ATL1) is a dynamin-related GTPase anchored in the ER membrane that fuses endoplasmic reticulum tubules to build the interconnected ER network. It is highly expressed in the nervous system, and mutations in ATL1 cause hereditary spastic paraplegia (SPG3A).
| Target | Atlastin-1 (gene ATL1; UniProt Q8WXF7, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 63.5 kDa |
| Observed MW | 64 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human 293T cells, human SiHa cells, human SH-SY5Y cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human adenocarcinoma of the right colon tissue, human cervical cancer tissue, human lymphoma tissue, human stomach cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): U87 cells.
Immunogen
Synthetic peptide from the middle region of human SPG3A/ATL1. Sequence identity with the mouse and rat orthologs: 93.8% and 100%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places atlastin-1 in the endoplasmic reticulum membrane, Golgi apparatus membrane and cell projection. Tissue expression noted by UniProt (human): Expressed predominantly in the adult and fetal central nervous system. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
